Free shipping on all orders over $ 500

GW842166X

Cat. No. M3282

All AbMole products are for research use only, cannot be used for human consumption.

GW842166X Structure
Size Price Availability
5mg USD 90  USD90 Out of stock
10mg USD 140  USD140 Out of stock
25mg USD 220  USD220 Out of stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

GW842166X shows similar potency and efficacy for rat and human recombinant CB2 receptors with EC50 of 91 nM and 63nM, respectively. GW842166X exhibits full agonist potency with an EC50 of 133 nM and Emax of 101% in cyclase assays. GW842166X exhibits weak agonist potency with an EC50 of 7.780 μM and Emax of 84% in FLIPR assays.GW842166X has an oral bioavailability of 58% and a half-life of 3 h when dosed orally in the rat. GW842166X has extremely high potency with an oral ED50 of 0.1 mg/kg and shows full reversal of hyperalgesia at 0.3 mg/kg in the FCAa model of inflammatory pain. GW842166X orally administrated at a dose of 15 mg/kg for 8 days produced a significant reversal of the CCI induced decrease in paw withdrawal threshold in a rat model of neuropathic pain.

Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models rat model of neuropathic pain
Formulation saline
Dosages 15 mg/kg
Administration Orally administrated once daily for 8 days
Chemical Information
Molecular Weight 449.25
Formula C18H17Cl2F3N4O2
CAS Number 666260-75-9
Solubility (25°C) DMSO 10 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Hao Yu, et al. The Neuroprotective Effects of the CB2 Agonist GW842166x in the 6-OHDA Mouse Model of Parkinson's Disease

[2] Hai-Yan Qian, et al. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies

[3] Hai-Yan Qian, et al. Development of Quinazoline/Pyrimidine-2,4(1 H,3 H)-diones as Agonists of Cannabinoid Receptor Type 2

[4] Jiong-jiong Chen, et al. The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies

[5] Gerard M P Giblin, et al. Discovery of 2-[(2,4-dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a selective CB2 receptor agonist for the treatment of inflammatory pain

Related Cannabinoid Products
UCM707 

UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of Anandamide.

SCH 336

SCH 336 is a potent, selective, inverse and orally active CB2 agonist.

JTE-907 

JTE-907 is a highly selective, orally active CB2 receptor inverse agonist and exerts anti-inflammatory effects in vivo.

LEI-101 

LEI-101 is a potent, selective, and orally bioavailable cannabinoid CB2 receptor agonist, with a pEC50 of 8 for hCB2, and a pKi of less than 4 for hERG.

AEF0117 

AEF0117 is a signaling-specific inhibitor of the cannabinoid receptor 1 (CB1-SSi).

  Catalog
Abmole Inhibitor Catalog




Keywords: GW842166X supplier, Cannabinoid, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.